Postplacental Intrauterine Device Insertion: A Mixed Methods Assessment of Women's Experience

NCT ID: NCT02312726

Last Updated: 2016-04-04

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 135 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-11-30
• Study Completion Date: 2015-03-31

Brief Summary

The primary objective of this mixed methods pilot study is to understand women's experiences with postplacental intrauterine device (IUD) insertion through postpartum semi-structured interviews. For secondary objectives, the investigators will collect visual analog scale (VAS) and verbal rating score (VRS) data on women's pain experienced just before and immediately after IUD insertion. The investigators will perform postpartum interviews in each group until we reach thematic saturation. The investigators will recruit at least 60 women (30 each in the epidural and no epidural group) from the University of New Mexico Hospital (UNMH) affiliated antenatal clinics to conduct our quantitative data analysis.

Detailed Description

Postplacental IUD insertion following vaginal or cesarean delivery is as effective in preventing pregnancy as interval insertion, and it is utilized more often in other countries such as China, Mexico and Egypt compared with the US (Celen, Moroy et al. 2004; Eroglu, Akkuzu et al. 2006; Kapp and Curtis 2009; Grimes, Lopez et al. 2010). In addition, current evidence supports the safety and superior cost effectiveness of IUD use (Trussell, Lalla et al. 2009; ACOG 2011). Postplacental IUD insertion is practiced routinely in US hospitals with active family planning faculty (including University of New Mexico Hospital), and has become standard of care for postpartum contraception options counseling in these institutions. Despite ample evidence supporting the safety and effectiveness of postplacental IUD insertion, the practice is uncommon among US providers and many women remain unaware of this option. Reasons for underutilization in the US may include lack of reimbursement, sufficient provider knowledge and training, and patient awareness.

Postplacental IUD insertion is also an attractive method for provision of postpartum contraception for several reasons: women are motivated to initiate contraception, they are not pregnant, and access to medical care is readily available.

Pain is a subjectively complex and universal experience which encompasses more experiential aspects than objective measurements of physical pain can capture. We know that interval IUD placement is painful, and that anxiety and fear of pain can be a barrier to IUD uptake, particularly among adolescent women (Allen, Bartz et al. 2009). Pain and low satisfaction with the IUD insertion procedure may limit patients' endorsement of the method to other women. There is insufficient research examining the patient's subjective experience with postplacental IUD placement. In addition, there is limited data about the physical pain level associated with postplacental IUD insertion.

Several studies have examined the efficacy of interventions to reduce pain for interval IUD insertion for nulliparous and multiparous women (Hubacher, Reyes et al. 2006; Edelman, Schaefer et al. 2011; Maguire, Davis et al. 2012; Swenson, Turok et al. 2012). Procedural aspects and clinical circumstances of postplacental IUD insertion differ substantially from those associated with interval insertion, preventing extrapolation of findings from studies of interval IUD insertion to postplacental insertion.

Specific aims:

1. Obtain an understanding of women's experiences with ring forceps postplacental IUD insertion through semi-structured interviews conducted prior to discharge from the hospital.

2. Establish objective assessments of physical pain associated with ring forceps postplacental IUD insertion using the 100mm Visual Analog Scale (VAS) and a categorical Verbal Rating Scale (VRS).

Participants will be recruited within the third trimester of pregnancy, when standard counseling typically occurs to address postpartum contraception options with patients; this usually occurs at 30 weeks gestation or later. The pain score assessment and interview data collection for each participant will take place while the patient is admitted for vaginal delivery at the University of New Mexico Hospital (UNMH).

The primary and secondary endpoints will occur at the conclusion of study enrollment when the last postpartum interview has been completed (when we have reached thematic saturation), and when we have at least 30 pain score assessments for the epidural and no epidural groups. The study is not designed to detect a difference in VAS scores between those women who have an epidural and those who do not (a power analysis was not performed), but rather this secondary objective is intended to establish the mean VAS score for each group. Because women will not know for certain if they will elect a labor epidural at the time of antenatal recruitment and because some women may not get undergo postplacental IUD placement for obstetric reasons (e.g., chorioamnionitis, postpartum bleeding, etc), it may be necessary to recruit more women than needed to achieve 30 women for each group. Up to 175 women will be recruited in the study.

When a participant presents to UNMH L&D to deliver her baby, we will confirm her ongoing desire to participate in the study, and will review the expectations for participation. We will confirm that the subject continues to meet the inclusion and exclusion criteria. Following vaginal birth, all eligible participants will undergo postplacental IUD insertion using the standardized ring forceps technique under ultrasound guidance, within 10-30 minutes of vaginal delivery, per standard of care for this procedure.

We will obtain a VAS and VRS score after the placenta delivers and prior to inserting the IUD, and a second set of scores within 5 minutes of insertion. We will assess provider ease of procedure using a four-point Likert scale. Prior to discharge from the hospital, we will confirm that subjects remain willing to participate in the postpartum interview portion of the study. If they elect to continue participation, they will undergo a semi-structured interview designed to explore their perceptions of the postpartum IUD insertion experience. Participants will have an appointment with their primary obstetric providers within two weeks of delivery for an IUD string check, per standard of care. We will not collect data from the postpartum IUD string check visit.

Data will be managed with the following methods: 1) Only the research team will have access to the data; 2) The data will be stored separately from consents; 3) Data sheets will be coded with the participant's assigned study code.

Data will be stored using the following methods: 1) The UNM Redcap database reposing study data will not contain unique patient identifiers; 2) The database for both quantitative and qualitative data will be stored on a secure, password protected server; 3) The identifiers will be linked to the patient's code number on a spreadsheet in a secure, designated password protected computer in the UNMH Ob-Gyn Department.

Data will be destroyed using the following methods: 1) Audio recordings of the interviews will be erased once they have been transcribed; 2) The link between study code and unique participant identifiers will be destroyed when the study is closed through the UNM Human Research Protections Office; 3) Study records will be kept for a minimum of three years; 4) HIPAA authorizations will be retained for a minimum of six years.

This study poses not more than minimal risk to subjects. There is a small risk that protected health information will be identified with study data. Study participation may be considered inconvenient by subjects.

The subjects will be permitted to withdraw from the study at any time without any effect on their access or options for care. The investigators have the right to end a subject's participation in this study if they determine that she no longer meets inclusion or exclusion criteria or if they, for whatever reason, believe that it is not in her best interests to continue participation. The investigators may also withdraw a subject if they determine that the subject is not following study protocol.

No further data collection will occur on a participant who withdraws from this study. The Institutional Review Board (IRB) will be notified of such withdrawals per IRB protocol.

Conditions

Contraception

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Epidural group

Participants who elect to have an epidural anesthesia during labor, delivery and postplacental IUD insertion

Postplacental IUD insertion

Intervention Type: PROCEDURE

Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.

Non Epidural group

Participants who elect not to have epidural anesthesia during labor, delivery and postplacental IUD insertion

Postplacental IUD insertion

Intervention Type: PROCEDURE

Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.

Interventions

Postplacental IUD insertion

Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.

Intervention Type: PROCEDURE

Other Intervention Names

Immediate postpartum IUD insertion

Eligibility Criteria

Inclusion Criteria

• English-speaking or Spanish-speaking only (SSO) women
• Women who express a desire to have an IUD inserted immediately following anticipated vaginal delivery.

Exclusion Criteria

• Unanticipated cesarean delivery
• Chorioamnionitis
• Significant postpartum hemorrhage (estimated blood loss requiring intervention beyond standard therapy and not resolved within approximately 10 minutes)
• Third or fourth degree obstetric vaginal laceration
• Manual extraction of the placenta
• Untreated gonorrhea, chlamydia and/or trichomoniasis
• Known or suspected distorted uterine cavity
• Current use of controlled substances for chronic pain management
• Current substance abuse/ addiction.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Society of Family Planning

OTHER

Sponsor Role: collaborator

University of New Mexico

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rameet H Singh, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

UNM OB GYN Division of Family Planning

Locations

University of New Mexico Health Sciences Center

Albuquerque, New Mexico, United States

Countries

United States

References

ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol. 2011 Jul;118(1):184-196. doi: 10.1097/AOG.0b013e318227f05e. No abstract available.

Reference Type: BACKGROUND

PMID: 21691183 (View on PubMed)

Allen RH, Bartz D, Grimes DA, Hubacher D, O'Brien P. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007373. doi: 10.1002/14651858.CD007373.pub2.

Reference Type: BACKGROUND

PMID: 19588429 (View on PubMed)

Celen S, Moroy P, Sucak A, Aktulay A, Danisman N. Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices. Contraception. 2004 Apr;69(4):279-82. doi: 10.1016/j.contraception.2003.12.004.

Reference Type: BACKGROUND

PMID: 15033401 (View on PubMed)

Edelman AB, Schaefer E, Olson A, Van Houten L, Bednarek P, Leclair C, Jensen JT. Effects of prophylactic misoprostol administration prior to intrauterine device insertion in nulliparous women. Contraception. 2011 Sep;84(3):234-9. doi: 10.1016/j.contraception.2011.01.016. Epub 2011 Mar 3.

Reference Type: BACKGROUND

PMID: 21843686 (View on PubMed)

Eroglu K, Akkuzu G, Vural G, Dilbaz B, Akin A, Taskin L, Haberal A. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception. 2006 Nov;74(5):376-81. doi: 10.1016/j.contraception.2006.07.003. Epub 2006 Sep 15.

Reference Type: BACKGROUND

PMID: 17046378 (View on PubMed)

Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Stanwood NL. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev. 2010 May 12;(5):CD003036. doi: 10.1002/14651858.CD003036.pub2.

Reference Type: BACKGROUND

PMID: 20464722 (View on PubMed)

Hubacher D, Reyes V, Lillo S, Zepeda A, Chen PL, Croxatto H. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol. 2006 Nov;195(5):1272-7. doi: 10.1016/j.ajog.2006.08.022.

Reference Type: BACKGROUND

PMID: 17074548 (View on PubMed)

Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. Contraception. 2009 Oct;80(4):327-36. doi: 10.1016/j.contraception.2009.03.024. Epub 2009 Aug 29.

Reference Type: BACKGROUND

PMID: 19751855 (View on PubMed)

Maguire K, Davis A, Rosario Tejeda L, Westhoff C. Intracervical lidocaine gel for intrauterine device insertion: a randomized controlled trial. Contraception. 2012 Sep;86(3):214-9. doi: 10.1016/j.contraception.2012.01.005. Epub 2012 Feb 9.

Reference Type: BACKGROUND

PMID: 22325115 (View on PubMed)

Speroff L, Mishell DR Jr. The postpartum visit: it's time for a change in order to optimally initiate contraception. Contraception. 2008 Aug;78(2):90-8. doi: 10.1016/j.contraception.2008.04.005. Epub 2008 Jun 12. No abstract available.

Reference Type: BACKGROUND

PMID: 18672108 (View on PubMed)

Swenson C, Turok DK, Ward K, Jacobson JC, Dermish A. Self-administered misoprostol or placebo before intrauterine device insertion in nulliparous women: a randomized controlled trial. Obstet Gynecol. 2012 Aug;120(2 Pt 1):341-7. doi: 10.1097/AOG.0b013e31825d9ec9.

Reference Type: BACKGROUND

PMID: 22825094 (View on PubMed)

Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception. 2009 Jan;79(1):5-14. doi: 10.1016/j.contraception.2008.08.003. Epub 2008 Sep 25.

Reference Type: BACKGROUND

PMID: 19041435 (View on PubMed)

Other Identifiers

UNM HSC 13-440

Identifier Type: -

Identifier Source: org_study_id